---
schema_version: "secwatch.filing_event.v1"
accession: "0001999480-25-000075"
form_type: "8-K"
ticker: "ANRO"
cik: "0001999480"
company_name: "Alto Neuroscience, Inc."
filed_at: "2025-08-13T23:59:59+00:00"
generated_at: "2026-05-17T14:03:54.144912+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Alto Neuroscience Q2 net loss $17.7M; ALTO-207 acquisition expands TRD pipeline; data readouts ahead

## Summary
- Net loss $17.7M in Q2 2025 vs $16.0M in Q2 2024; cash $148.1M expected to fund operations into 2028.
- Acquired ALTO-207 (pramipexole/ondansetron) from Chase; Phase 2b in TRD planned by mid-2026.
- ALTO-101 Phase 2 POC topline data for CIAS expected 2H 2025; ALTO-300 Phase 2b MDD data mid-2026.
- ALTO-100 Phase 2b bipolar depression data expected 2H 2026; ALTO-203 showed positive pharmacodynamic results.
- Appointed Raymond Sanchez, M.D., to Board; class structure reconstituted, committee assignments updated.

## SEC filing metadata
- accession: 0001999480-25-000075
- form_type: 8-K
- ticker: ANRO
- cik: 0001999480
- company_name: Alto Neuroscience, Inc.
- filed_at: 2025-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1999480/000199948025000075/0001999480-25-000075-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1999480/000199948025000075/alto-20250812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001999480-25-000075
- JSON: https://secwatch.observer/filing/0001999480-25-000075.json
- Plain text: https://secwatch.observer/filing/0001999480-25-000075.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.